MGNX
MacroGenics, Inc.
$4.16
-1.19%
2026-05-29
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Key Fundamentals
Forward P/E
-2.20
EPS (TTM)
$-1.18
ROE
-86.9%
Revenue Growth (YoY)
113.0%
Profit Margin
-49.9%
Debt/Equity
66.13
Price/Book
3.34
Beta
1.08
Market Cap
$186.5M
Avg Volume (10D)
582K
Recent Breakout Signals
No recent breakout signals detected for MGNX.
Recent Price Range (60 Days)
60D High
$4.64
60D Low
$2.01
Avg Volume
1.3M
Latest Close
$4.16
Get breakout alerts for MGNX
Sign up for Breakout Scanner to receive daily notifications when MGNX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
MacroGenics, Inc. (MGNX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MGNX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MGNX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.